Finasteride USP 5mg


Finasteride is indicated for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to: - cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH - reduce the incidence of acute urinary retention and the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.


The recommended adult dose is one 5 mg tablet daily, with or without food. Finasteride can be administered alone or in combiantion with the alpha-blocker doxazosin (see section 5.1 'Pharmacodynamic properties'). Although early improvement in symptoms may be seen, treatment for at least six months may be necessary to assess whether a beneficial response has been achieved. Thereafter, treatment should be continued long term. No dosage adjustment is required in the elderly or in patients with varying degrees of renal insufficiency (creatinine clearances as low as 9 ml/min). There are no data available in patients with hepatic insufficiency. Finasteride is contra-indicated in children.